Kyverna Therapeutics, Inc.
KYTXNASDAQHealthcare● Active
$7.47
$-0.48(-6.04%)
Market Cap$327124066
P/E Ratio—
52W High$13.67
52W Low$2.52
Kyverna Therapeutics, Inc. (KYTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KYTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.66
Est. -$0.75 · +12.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
KYTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.67 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.75 | -$0.66 | +12.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.84 | -$0.80 | +5.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.97 | -$0.85 | +12.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$1.00 | -$0.97 | +3.0% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$1.21 | -$1.03 | +14.9% | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.87 | -$0.88 | -1.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.77 | -$0.80 | -3.9% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.67
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.66
EPS Est.
-$0.75
EPS Surpr.
+12.0%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.80
EPS Est.
-$0.84
EPS Surpr.
+5.3%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$0.97
EPS Surpr.
+12.4%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.97
EPS Est.
-$1.00
EPS Surpr.
+3.0%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$1.03
EPS Est.
-$1.21
EPS Surpr.
+14.9%
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.87
EPS Surpr.
-1.1%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.80
EPS Est.
-$0.77
EPS Surpr.
-3.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.51 | $0.51 | $0.51 | 3 |
| Q3 FY2028 | $0.22 | $0.22 | $0.22 | 2 |
| Q2 FY2028 | $-0.10 | $-0.10 | $-0.10 | 2 |
| Q1 FY2028 | $-0.27 | $-0.27 | $-0.27 | 3 |
| Q4 FY2027 | $-0.54 | $-0.54 | $-0.54 | 2 |
| Q3 FY2027 | $-0.67 | $-0.67 | $-0.67 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +12.0% | $10.34 | $10.23 | -1.06% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +5.3% | $7.87 | $8.03 | +2.03% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +12.4% | $7.00 | $7.33 | +4.71% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +3.0% | $3.10 | $3.02 | -2.58% |
| ▲ Q2 FY2025 | May 13, 2025 | +14.9% | $2.21 | $2.32 | +4.98% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -1.1% | $2.50 | $2.36 | -5.60% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -3.9% | $5.22 | $5.06 | -3.07% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +4.3% | $6.56 | $6.53 | -0.46% |
Q2 FY2026-1.06%
Report Date
May 12, 2026
EPS Beat/Miss
+12.0%
Price Before
$10.34
Price After
$10.23
Q1 FY2026+2.03%
Report Date
Mar 26, 2026
EPS Beat/Miss
+5.3%
Price Before
$7.87
Price After
$8.03
Q4 FY2025+4.71%
Report Date
Nov 12, 2025
EPS Beat/Miss
+12.4%
Price Before
$7.00
Price After
$7.33
Q3 FY2025-2.58%
Report Date
Aug 12, 2025
EPS Beat/Miss
+3.0%
Price Before
$3.10
Price After
$3.02
Q2 FY2025+4.98%
Report Date
May 13, 2025
EPS Beat/Miss
+14.9%
Price Before
$2.21
Price After
$2.32
Q1 FY2025-5.60%
Report Date
Mar 27, 2025
EPS Beat/Miss
-1.1%
Price Before
$2.50
Price After
$2.36
Q4 FY2024-3.07%
Report Date
Nov 13, 2024
EPS Beat/Miss
-3.9%
Price Before
$5.22
Price After
$5.06
Q3 FY2024-0.46%
Report Date
Aug 12, 2024
EPS Beat/Miss
+4.3%
Price Before
$6.56
Price After
$6.53
Avg Beat Reaction+1.27%
Avg Miss Reaction-4.33%
Beat Rate6 / 8 quarters
Largest Move-5.60% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KYTX ends December
Kyverna Therapeutics, Inc. (KYTX) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.66 — beating the analyst consensus of $-0.75 by +12.0%. KYTX has beaten EPS estimates for 5 consecutive quarters. The next KYTX earnings date is expected around September 1, 2026.
Each quarter, investors track KYTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KYTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KYTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KYTX earnings · 5 questionsKyverna Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. KYTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KYTX historically reports after market close (AMC).
KYTX earnings datewhen is KYTX earningsKYTX next earnings datewhen does KYTX report earningsKYTX earnings calendar
▸ Source: FMP · Kyverna Therapeutics, Inc. SEC filings · US GAAP · Kyverna Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026